Epigral reversed its epoxy strategy within six months
The board approved a 125,000-ton epoxy resin plant after management said in January it had no plan to enter the business, leaving the pivot unexplained.
What's new
- Q1 FY27 revenue rose 15% to ₹709 cr; EBITDA margin fell to 25.0% from 27.0%.
- Board approved entry into epoxy resin and formulations, 125,000 tons per annum.
- Net debt/EBITDA worsened to 0.8x from 0.6x as debt rose to ₹474 cr.
- Combined new projects can generate peak revenue of ₹1,300-1,500 cr.
Themes from the call
Demand
CPVC utilization was 50-55% due to pipe makers' inventory management; caustic soda ran at 75%, while chlorobenzenes hit 100%.
Margins
EBITDA margin contracted 200 bps to 25.0% on raw-material and logistics volatility, though PAT grew 25% to ₹99 cr on a deferred-tax adjusted base.
Capital allocation
Capex of ₹400 cr each in FY27/FY28 will be funded 60% by debt; the epoxy entry adds ₹600 cr of investment with a target ROCE of ~20%.
Guidance watch
- Combined new projects revenue potential of ₹1,300-1,500 cr, supporting company top line of ~₹5,000 cr at optimum levels.
- Top-line and bottom-line CAGR of 15-20% over 3-5 years; internal target of 20% or higher growth.
- Capex of ₹400 cr each in FY27 and FY28, funded 60% debt and 40% internal accruals.
- Pilot facilities for epoxy and MPP to be operational by Q2 FY27; MPP completion in FY28.
Risk flags
- Strategic reversals on epoxy and caustic soda trade balance without explanation raise credibility concerns.
- CPVC demand softer than expected at 50-55% utilization; monsoon and PVC price volatility add near-term uncertainty.
- Net debt/EBITDA increased to 0.8x from 0.6x; debt is rising to fund expansion.
- Management refused to provide EBITDA margin guidance for the new projects or break down the ₹600 cr epoxy capex.
Key quotes
-
"As of now, we have no plan to going into the forward integration... we are not taking anything on the epoxy side."
— Epigral management, Jan 2026 call -
"Our internal target is to grow at 20% or higher. Over a 3-5 year period, we target a CAGR of 15% to 20% for both top line and bottom line."
— Mohit Patel, Chairman and Managing Director, Jul 2026 call
The brief
Epigral's strategy whiplash is the real story this quarter. In January the company told investors it had no plan to enter epoxy. In July the board approved a 125,000-ton epoxy resin plant — a material shift in capital allocation and strategic direction with no explanation given. The same call carried another quiet reversal: India's caustic soda market was redefined from net exporter to net importer because of alumina expansions. Neither pivot was reconciled with earlier statements. The growth narrative rests on a dramatic upward revision of internal targets — from 10-12% volume growth in May to 20% or higher in July — but the bridge between those numbers is missing.
The underlying business numbers tell a mixed story. Revenue grew 15% to ₹709 cr, EBITDA margin contracted to 25.0% from 27.0%, and PAT rose on a one-off-adjusted base. CPVC utilization ran at only 50-55%, with demand weaker than expected. Caustic soda and chlorobenzenes held up better. The expansion plan is ambitious: combined new projects could bring ₹1,300-1,500 cr of revenue and support a ₹5,000 cr top line. But management's refusal to provide a project-level margin breakdown or explain the strategic about-face leaves the street making assumptions.
Chairman Mohit Patel spoke of a 15-20% CAGR over 3-5 years. The target is ambitious on paper. But credibility, like a strategy, cannot be reversed every six months without cost.
Epigral's growth story is ambitious, but the strategy whiplash makes the numbers harder to trust. Credibility first.